|Bid||0.00 x 900|
|Ask||37.85 x 800|
|Day's Range||30.20 - 31.25|
|52 Week Range||20.20 - 37.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Most investors find it challenging to find companies with prospective double-digit growth rates that are also financially robust. These hidden gems also add meaningful upside to a portfolio, should theRead More...
Botox faces a delay in getting to market, Allergan is anything but frozen. "Of course, it's always interesting when a company takes more time to get to market," Allergan chief commercial officer William Meury said at the Bank of America healthcare conference in Las Vegas on Thursday, May 17. Meury's appearance at the conference came a day after competitor Evolus Inc.
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the expansion of its executive leadership team with the appointment of Caryn McDowell as Senior Vice President, General Counsel, and Corporate Secretary, effective May 1, 2018. Ms. McDowell will report to President and Chief Executive Officer Dan Browne, and will serve as Revance’s General Counsel, leading all legal, governance, and compliance initiatives. “Caryn brings extensive legal experience in the biopharma and healthcare sectors, advising companies developing and commercializing novel drug products,” said Mr. Browne.
Patients are already clamoring for “the longer acting Botox,” a not-yet approved treatment from Revance Therapeutics, CEO Dan Browne told Bloomberg News in an interview Friday. The launch won’t happen for another two years or so, and while many patients want more time looking younger, doctors are looking for a longer acting product for therapeutic goals. "People underestimate the power of this data,” Browne said, he’s expecting it to be a “major de-risking event” for Revance when results from the study, known as “Sakura” read out later this year.
Dan Browne, co-founder, president and CEO of Revance Therapeutics, tells Jim Cramer his company is developing an alternative to Botox.
Biotech stocks are at the mercy of market-moving catalysts, and Cantor Fitzgerald analyst Louise Chen outlined potential outlined potential stock-moving events for eight biotech names in a Monday report. ...
Revance Therapeutics Inc (NASDAQ: RVNC ) has dropped 9 percent since the start of the year, but it's begun a path to redemption through a new, respected advocate. The Rating Goldman Sachs analysts Dana ...
Revance Therapeutics Inc (NASDAQ:RVNC) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Mylan and Revance Therapeutics say they have teamed up to develop and commercialize a proposed biosimilar or copy of Allergan's popular Botox, potentially ratcheting up pressure on the drugmaker.
Allergan tanked to a five-year low Thursday after Mylan and Revance announced their plan to bring a Botox copycat to the market.
The pharmaceutical company unveiled a collaboration and license pact with Revance Therapeutics to develop and commercialize a proposed biosimilar or copy of Allergan's Botox.
The Newark, California-based company said it had a loss of $1.14 per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...
Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc's blockbuster Botox wrinkle treatment. The deal includes an upfront payment of $25 ...
Mylan on Wednesday reported adjusted profit of $1.43 per share on revenue of $3.24 billion for its fourth quarter.
Individual investors like stocks with a high growth potential. These companies have a strong outlook that can bring a significant upside to your portfolio, regardless of market cyclicality. I wouldRead More...
The chief commercial officer of the Dublin drugmaker describes the long-term outlook for the medical aesthetics business as 'exceptional.'
Jim Cramer hears from Revance Therapeutics co-founder, President and CEO Dan Browne about his biotechnology therapy that competes with Allergan's Botox.